Intellia Therapeutics Reports Q1 2026 Financial Results with Revenue Decline and Reduced Operating Expenses

Intellia Therapeutics, Inc. reported its financial results for the first quarter of 2026, revealing a collaboration revenue of $15.0 million, a decrease from $16.6 million in the same period last year. The decline in revenue is attributed primarily to reduced earnings from its collaboration agreement with AvenCell Therapeutics, as well as the absence of a milestone payment that was recognized in the previous year under the Regeneron agreement. Despite the drop in revenue, the company managed to reduce its total operating expenses to $115.6 million from $137.4 million, leading to an operating loss of $100.5 million, an improvement from the $120.8 million loss reported in Q1 2025.

Research and development expenses saw a significant decrease of 26% year-over-year, totaling $80.7 million, down from $108.4 million. This reduction was driven by lower external costs associated with the development of its lead product candidates, lonvoguran ziclumeran (lonvo-z) and nexiguran ziclumeran (nex-z), as well as decreased employee-related expenses following a workforce reduction in January 2025. General and administrative expenses, however, increased by $5.8 million to $34.8 million, primarily due to higher legal and consulting costs related to the company's commercial infrastructure buildout.

As of March 31, 2026, Intellia's total assets were reported at $758.8 million, a decrease from $842.1 million at the end of 2025. The company's cash and cash equivalents stood at $134.7 million, down from $155.5 million, while marketable securities decreased to $241.3 million from $294.4 million. The company’s total liabilities also decreased significantly to $137.8 million from $170.7 million, reflecting a reduction in accrued expenses and current liabilities.

Looking ahead, Intellia is preparing for the commercial launch of lonvo-z, following positive topline data from its Phase 3 clinical trial for hereditary angioedema, with plans to submit a biologics license application to the FDA in the second half of 2026. The company expects its current cash, cash equivalents, and marketable securities, along with proceeds from a recent equity offering, to fund operations through at least 2028. Intellia continues to focus on advancing its CRISPR-based therapies while managing its expenses strategically to support its clinical and commercial objectives.